Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 335

“2nd Annual Next Gen Immuno-Oncology Congress”

Posted by fidest press agency su sabato, 31 agosto 2019

The current revolution in immuno-oncology is being driven by Antibody Drug Conjugates, Immune Checkpoint Inhibitors, Bispecific Antibodies, and Cell Therapies.Clinical trials have shown that cancer patients can tolerate this immune-based treatment more effectively than conventional treatments like chemotherapy and radiotherapy. It’s clearly one of the hottest fields of Biopharma which has gained momentum in the past few years.With more than 45 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in the development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors, and Cellular Therapy.
Meet and network with experts from leading universities and industry sharing their knowledge on Preclinical and Translational Immuno-Oncology Developments, Next Gen CAR-T Cell Therapy, Immune Checkpoint Inhibitors, Monoclonal, and Bispecific Antibodies and more.
A platform to meet experts from Pharma, biopharma and biotech companies and increase your learning in Monoclonal and Bispecific Antibodies, Cell Therapy and Immune Checkpoint Inhibitors.


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di

Stai commentando usando il tuo account Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

%d blogger hanno fatto clic su Mi Piace per questo: